Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

XSSC:603707 Stock Report

Market Cap: CN¥17.7b

Nanjing King-Friend Biochemical PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 6.6% annually. Revenues have been growing at an average rate of 6.9% per year. Nanjing King-Friend Biochemical PharmaceuticalLtd's return on equity is 11.2%, and it has net margins of 19.3%.

Key information

-18.38%

Earnings growth rate

-18.81%

EPS growth rate

Pharmaceuticals Industry Growth10.90%
Revenue growth rate6.86%
Return on equity11.16%
Net Margin19.28%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Nanjing King-Friend Biochemical PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:603707 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 253,805734521324
31 Dec 243,924826499330
30 Sep 243,877-423472376
30 Jun 243,770-409467396
31 Mar 243,628-345510380
31 Dec 233,931-189563372
30 Sep 234,0041,023581315
30 Jun 234,0411,101674309
31 Mar 233,8441,093643278
31 Dec 223,7131,091618264
30 Sep 223,7581,122591229
30 Jun 223,9111,118610231
31 Mar 223,9801,116596241
31 Dec 213,6871,059608221
30 Sep 213,5371,038600197
30 Jun 213,270953570188
31 Mar 213,064875588174
31 Dec 202,915806559188
30 Sep 202,800770541189
30 Jun 202,689724497187
31 Mar 202,594660466178
31 Dec 192,470605422166
30 Sep 192,224539418138
30 Jun 192,027487371125
31 Mar 191,875452320113
31 Dec 181,700425284101
30 Sep 181,633425206118
30 Jun 181,479418131128
31 Mar 181,325380103102
31 Dec 171,1133149477
30 Sep 179152766944
30 Jun 177581931130
31 Mar 176682841270
31 Dec 16582257950
31 Dec 1546988550
31 Dec 1441650430

Quality Earnings: 603707 has high quality earnings.

Growing Profit Margin: 603707 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 603707's earnings have declined by 18.4% per year over the past 5 years.

Accelerating Growth: 603707 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 603707 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.3%).

Return on Equity

High ROE: 603707's Return on Equity (11.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 20:41
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yong Jian LiChina Merchants Securities Co. Ltd.
Shitong HanCitic Securities Co., Ltd.